loading page

MANα1-2MAN decorated liposomes enhance the immunogenicity induced by a DNA vaccine against BoHV-1
  • +10
  • Claudia Kornuta,
  • Juan Bidart,
  • Ivana Soria,
  • Mariela Gammella,
  • Valeria Quattrocchi,
  • Dadin Moore,
  • Yanina Hecker,
  • Felipe Cheuquepan Valenzuela,
  • Juan Pappalardo,
  • Stefano Salmaso,
  • Vladimir Torchilin,
  • Patricia Zamorano,
  • Cecilia Langellotti
Claudia Kornuta
Instituto Nacional de Tecnologia Agropecuaria

Corresponding Author:[email protected]

Author Profile
Juan Bidart
Instituto Nacional de Tecnologia Agropecuaria
Author Profile
Ivana Soria
Instituto Nacional de Tecnologia Agropecuaria
Author Profile
Mariela Gammella
Instituto Nacional de Tecnologia Agropecuaria
Author Profile
Valeria Quattrocchi
Instituto Nacional de Tecnologia Agropecuaria
Author Profile
Dadin Moore
Estacion Experimental Agropecuaria Balcarce
Author Profile
Yanina Hecker
Estacion Experimental Agropecuaria Balcarce
Author Profile
Felipe Cheuquepan Valenzuela
Estacion Experimental Agropecuaria Balcarce
Author Profile
Juan Pappalardo
Estación Experimental Agropecuaria Bariloche
Author Profile
Stefano Salmaso
Universita degli Studi di Padova
Author Profile
Vladimir Torchilin
Northeastern University
Author Profile
Patricia Zamorano
Instituto Nacional de Tecnología Agropecuaria
Author Profile
Cecilia Langellotti
CONICET
Author Profile

Abstract

New technologies in the field of vaccinology arise as necessity for treatment and control of many diseases. Currently modified live virus and inactivated vaccines used for Bovine Herpesvirus-1 (BoHV-1) have several disadvantages. Previous works for preventive treatment of BoHV-1 with DNA based vaccines have demonstrated the capability to induce humoral and cellular immune response. Nevertheless, it is well known that “naked” DNA induces low immunogenic response. Thus, loading of antigen encoding DNA sequences in liposomal formulations targeting dendritic cell receptors could be a promising strategy to better activate these antigen presenting cells (APC). In this work, DNA based vaccine encoding the truncated version of gD glycoprotein (pCIgD) of BoHV-1 was investigated alone and upon encapsulation on liposomal formulation coated with MANα1-2MAN-PEG-DOPE and LPS from Brucella ovis (pCIgD-Man-L) in mice and cattle assay. Results showed that the use of pCIgD-Man-L was capable to enhance the immune response in both animal models. Significant levels of humoral immunity were achieved when total antibody titers and isotypes were detected in sera and mucosa. For cellular immunity, specific viral lymphoproliferation was detected in the animals inoculated with pCIgD-Man-L. In addition, positively modulation of CD40 molecules on the surface of bovine dendritic cells (DCs) was observed when cells were stimulated and activated with vaccine formulations. When challenge assay was performed, bovines inoculated with pCIgD and liposome decorated with MANα1-2MAN-PEG-DOPE elicited better protection and diminished viral excretion. The results demonstrate the targeting of the MANα1-2MAN coated liposomes toward dendritic cells and their ability to boost the immunogenicity according to an adjuvant effect that results in long-lasting immunity. Liposome decorated with MANα1-2MAN-PEG-DOPE were for the first time tested as DNA based vaccine in cattle as preventive treatment of BoHV-1. These results open up new perspectives for the design of vaccine for the control of bovine rhinotracheitis.
13 Apr 2020Submitted to Transboundary and Emerging Diseases
27 Apr 2020Submission Checks Completed
27 Apr 2020Assigned to Editor
29 Apr 2020Review(s) Completed, Editorial Evaluation Pending
29 Apr 2020Editorial Decision: Revise Major
30 Apr 20201st Revision Received
30 Apr 2020Submission Checks Completed
30 Apr 2020Assigned to Editor
02 May 2020Reviewer(s) Assigned
26 May 2020Review(s) Completed, Editorial Evaluation Pending
27 May 2020Editorial Decision: Revise Minor
12 Jun 20202nd Revision Received
15 Jun 2020Submission Checks Completed
15 Jun 2020Assigned to Editor
15 Jun 2020Reviewer(s) Assigned
01 Jul 2020Review(s) Completed, Editorial Evaluation Pending
02 Jul 2020Editorial Decision: Accept